Beyond sotatercept, what is the future of TGFb/activin signaling in PAH?

Presented at PVRI 2026 Congress by Paul Yu, Mass General Brigham

Summary

PH treatment involves complex signalling pathways, particularly the roles of BMP9 and TGF-beta. Challenges in understanding these pathways are discussed, along with the therapeutic potential of antagonising them. The content covers mechanisms of action, treatment effects, and clinical implications. It emphasises the role of apoptosis in vascular remodelling and highlights the need for further research to explore new therapeutic strategies.

Generated with AI, edited by PVRI